Catapres-tts-3 Patch
Product Images NDC 82089-103

17 FDA label images from Technomed Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Catapres-tts-3 (NDC 82089-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Technomed Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (0.1 mg Adhesive Cover Pouch)

Principal Display Panel (0.1 mg Adhesive Cover Pouch)
Label of an adhesive cover for Catapres-TTS-2 clonidine transdermal system patch. The cover does not contain active medication and is applied over the patch if necessary. The label includes usage warnings and instructions to refer to patient information for proper use.*
FDA Label Image

Principal Display Panel (0.2 mg Adhesive Cover Pouch)

Principal Display Panel (0.2 mg Adhesive Cover Pouch)
Two labels from adhesive covers for Catapres-TTS-2 clonidine transdermal system patches. Each label states it contains 1 adhesive cover without active medication, to be applied over the patch if necessary, and references patient instructions for use. Production codes and label identifiers are also visible.*
FDA Label Image

Principal Display Panel (0.3 mg Adhesive Cover Pouch)

Principal Display Panel (0.3 mg Adhesive Cover Pouch)
Packaging label for Catapres-TTS-2 clonidine transdermal system adhesive cover, containing a warning that it does not contain active medication and should be applied over the patch if necessary. The label advises to see patient instructions for use of the adhesive cover and is marked with identifiers including 15002A and 10003923/02.*
FDA Label Image

Catapres-tts-structure (Catapres Tts Structure)

Catapres-tts-structure (Catapres Tts Structure)
Chemical structure of clonidine, the active ingredient in Catapres-TTS-2 transdermal system. The diagram shows the molecular arrangement including a dichlorophenyl ring connected to an imidazoline group.*
FDA Label Image

Cross-section-table (Cross Section Table)

Cross-section-table (Cross Section Table)
An illustration showing the layered structure of the Catapres-TTS-2 clonidine transdermal system patch. The layers are labeled from top to bottom as Backing, Drug Reservoir, Control Membrane, Adhesive, and Slit Release Liner, depicting the patch's components for controlled drug delivery.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
Illustration showing the application of a Catapres-TTS-2 clonidine transdermal system patch on the skin. The diagram labels the 'PATCH' and an 'ADHESIVE COVER' to be applied over the patch if necessary, indicating proper placement on the upper arm.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
Packaging labels for Catapres-TTS transdermal system by Technomed Inc. The image shows two labeled packets: one containing the Catapres-TTS-1 patch with medication (clonidine transdermal system) and another containing a cover intended for use if the patch becomes loose.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
An instructional illustration showing hands peeling a protective backing off a Catapres-TTS-2 clonidine transdermal patch. The image demonstrates the application step of the transdermal system patch for human prescription use, produced by Technomed Inc.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
An instructional illustration showing hands peeling or handling a small patch or adhesive transdermal system, likely demonstrating how to remove or apply it.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
An instructional anatomical illustration depicting the application site of a transdermal patch on the upper arm, demonstrating proper patch placement for a clonidine transdermal system (Catapres-TTS-2). The image shows a hand placing the patch on the shoulder area, emphasizing correct adherence.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
An instructional illustration showing a Catapres-TTS-2 clonidine transdermal patch along with its adhesive cover. The cover includes a warning that it does not contain active medication and advises applying the patch over it if necessary, with a note to see patient instructions for use of the adhesive cover.*
FDA Label Image

Principal Display Panel (0.1 mg Patch Pouch Label)

Principal Display Panel (0.1 mg Patch Pouch Label)
Catapres-TTS-1 clonidine transdermal system patch label with programmed delivery of 0.1 mg clonidine per day for one week. Front label includes usage warning related to MRI procedures. Back label shows storage instructions, batch lot, expiration information, barcode, and manufacturer details (Alza Corporation, Vacaville, CA). Produced by Technomed Inc.*
FDA Label Image

Principal Display Panel (0.2 mg Patch Pouch Label)

Principal Display Panel (0.2 mg Patch Pouch Label)
Catapres-TTS-2 clonidine transdermal system patch packaging label showing front and back. The front states programmed delivery of 0.2 mg clonidine per day for one week, with MRI warning and Rx only status. The back includes a barcode, lot and expiration placeholders, storage instructions, manufacturer Alza Corporation, and trademark information for Catapres-TTS by Technomed Inc.*
FDA Label Image

Principal Display Panel (0.3 mg Patch Pouch Label)

Principal Display Panel (0.3 mg Patch Pouch Label)
Catapres-TTS-3 clonidine transdermal system patch label shows a programmed delivery of 0.3 mg clonidine per day for one week. The front panel includes warnings about MRI procedures, and the back panel instructs removal of the clear backing before use, storage conditions, and manufacturing information by Alza Corporation. The label references Technomed Inc. as the licensee.*
FDA Label Image

Principal Display Panel (0.1 mg Patch Pouch Carton)

Principal Display Panel (0.1 mg Patch Pouch Carton)
Label for Catapres-TTS-1 clonidine transdermal system patch containing 0.1 mg/day strength. The packaging states it includes 4 systems and 4 adhesive covers, providing programmed delivery of 0.1 mg clonidine per day for one week. It is for transdermal use only, labeled as a prescription human drug by Technomed Inc.*
FDA Label Image

Principal Display Panel (0.2 mg Patch Pouch Carton)

Principal Display Panel (0.2 mg Patch Pouch Carton)
The packaging label for Catapres-TTS-2 patch contains clonidine transdermal system with a strength of 0.2 mg per day. The label indicates each box contains 4 systems and 4 adhesive covers for transdermal delivery over one week. The labeler is Technomed Inc. The product is prescription-only, and the label includes warnings about MRI procedures and barcode information.*
FDA Label Image

Principal Display Panel (0.3 mg Patch Pouch Carton)

Principal Display Panel (0.3 mg Patch Pouch Carton)
Packaging label for Catapres-TTS-3 clonidine transdermal system patch by Technomed Inc. The label shows the 0.3 mg/day strength with 4 systems and 4 adhesive covers. It includes usage instructions indicating one week delivery, a barcode, and regulatory information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.